246 related articles for article (PubMed ID: 22504671)
1. [Cellular functions of BRCA genes - from basic science to therapeutics].
Miki Y
Gan To Kagaku Ryoho; 2012 Apr; 39(4):498-501. PubMed ID: 22504671
[TBL] [Abstract][Full Text] [Related]
2. [PARP inhibitors for cancer therapy].
Saito H; Miki Y
Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis.
Cousineau I; Abaji C; Belmaaza A
Cancer Res; 2005 Dec; 65(24):11384-91. PubMed ID: 16357146
[TBL] [Abstract][Full Text] [Related]
4. [BRCA1 and BRCA2 - pathologists starting kit].
Škapa P
Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
[TBL] [Abstract][Full Text] [Related]
5. Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forks.
Nagaraju G; Scully R
DNA Repair (Amst); 2007 Jul; 6(7):1018-31. PubMed ID: 17379580
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
7. BRCA2 regulates homologous recombination in response to DNA damage: implications for genome stability and carcinogenesis.
Abaji C; Cousineau I; Belmaaza A
Cancer Res; 2005 May; 65(10):4117-25. PubMed ID: 15899802
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 and BRCA2 protect against oxidative DNA damage converted into double-strand breaks during DNA replication.
Fridlich R; Annamalai D; Roy R; Bernheim G; Powell SN
DNA Repair (Amst); 2015 Jun; 30():11-20. PubMed ID: 25836596
[TBL] [Abstract][Full Text] [Related]
9. In brief: BRCA1 and BRCA2.
Foulkes WD; Shuen AY
J Pathol; 2013 Aug; 230(4):347-9. PubMed ID: 23620175
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair.
O'Donovan PJ; Livingston DM
Carcinogenesis; 2010 Jun; 31(6):961-7. PubMed ID: 20400477
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
Bouwman P; Jonkers J
Clin Cancer Res; 2014 Feb; 20(3):540-7. PubMed ID: 24270682
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
Talens F; Jalving M; Gietema JA; Van Vugt MA
Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
[TBL] [Abstract][Full Text] [Related]
13. Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy.
Hay T; Jenkins H; Sansom OJ; Martin NM; Smith GC; Clarke AR
Cancer Res; 2005 Nov; 65(22):10145-8. PubMed ID: 16287996
[TBL] [Abstract][Full Text] [Related]
14. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.
Yuan SS; Lee SY; Chen G; Song M; Tomlinson GE; Lee EY
Cancer Res; 1999 Aug; 59(15):3547-51. PubMed ID: 10446958
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair.
Bolderson E; Richard DJ; Zhou BB; Khanna KK
Clin Cancer Res; 2009 Oct; 15(20):6314-20. PubMed ID: 19808869
[TBL] [Abstract][Full Text] [Related]
16. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott CL
Asia Pac J Clin Oncol; 2011 Sep; 7(3):197-211. PubMed ID: 21884432
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in molecular genetics of breast cancer.
Pavelić K; Gall-Troselj K
J Mol Med (Berl); 2001 Oct; 79(10):566-73. PubMed ID: 11692153
[TBL] [Abstract][Full Text] [Related]
18. [On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
Gaziev AI
Radiats Biol Radioecol; 2014; 54(3):229-40. PubMed ID: 25764827
[TBL] [Abstract][Full Text] [Related]
19. BRCA in breast cancer: from risk assessment to therapeutic prediction.
Diamond JR; Borges VF; Eckhardt SG; Jimeno A
Drug News Perspect; 2009 Dec; 22(10):603-8. PubMed ID: 20140280
[TBL] [Abstract][Full Text] [Related]
20. Lower level of BRCA2 protein in heterozygous mutation carriers is correlated with an increase in DNA double strand breaks and an impaired DSB repair.
Arnold K; Kim MK; Frerk K; Edler L; Savelyeva L; Schmezer P; Wiedemeyer R
Cancer Lett; 2006 Nov; 243(1):90-100. PubMed ID: 16448746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
